KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Exchange Rate Effect (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Exchange Rate Effect for 17 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Exchange Rate Effect rose 103.4% to $5.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $195.0 million, a 242.34% increase, with the full-year FY2025 number at $195.0 million, up 242.34% from a year prior.
  • Exchange Rate Effect was $5.0 million for Q4 2025 at Bristol Myers Squibb, up from -$4.0 million in the prior quarter.
  • In the past five years, Exchange Rate Effect ranged from a high of $128.0 million in Q2 2025 to a low of -$147.0 million in Q4 2024.
  • A 5-year average of -$1.6 million and a median of -$6.0 million in 2023 define the central range for Exchange Rate Effect.
  • Peak YoY movement for Exchange Rate Effect: tumbled 494.44% in 2022, then skyrocketed 681.82% in 2025.
  • Bristol Myers Squibb's Exchange Rate Effect stood at -$54.0 million in 2021, then skyrocketed by 275.93% to $95.0 million in 2022, then decreased by 17.89% to $78.0 million in 2023, then crashed by 288.46% to -$147.0 million in 2024, then skyrocketed by 103.4% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for BMY's Exchange Rate Effect are $5.0 million (Q4 2025), -$4.0 million (Q3 2025), and $128.0 million (Q2 2025).